巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-05 22:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2022-01-15
2021-04-15
2021-11-10
2023-03-05
2023-02-26
2021-12-01
2023-07-27
2023-03-02
2021-08-16
2023-04-25
2022-01-12
2021-11-20
